Why psychedelic research stopped for decades

Between the early 1950s and the late 1960s, scientists published thousands of papers on psychedelic compounds such as LSD, psilocybin, and mescaline. Researchers at major universities and clinical institutions explored their potential in psychiatry, psychology, and the study of consciousness. Then, within a few short years, that research largely ground to a halt. For roughly three decades — a period sometimes called the psychedelic winter — clinical studies all but disappeared from the scientific landscape. The reasons were not primarily scientific. They were political, cultural, and regulatory.

A promising field, abruptly abandoned

By the mid-1960s, psychedelic research was a recognised and active field. Psilocybin, isolated by Swiss chemist Albert Hofmann in the late 1950s, was administered to human volunteers in academic settings from the early 1960s onward. Studies explored applications ranging from alcohol dependence to anxiety and mood disorders, and the work was published in mainstream journals. The research was not fringe; it received legitimate institutional and government support.

Yet by the early 1970s, clinical psychedelic research had effectively stopped. While ethical concerns about some early studies — questionable methodology, inadequate consent procedures — were genuine, historians generally agree that the decisive factors were political and regulatory rather than purely scientific.

The cultural backlash and political response

The late 1960s saw psychedelics move from the laboratory into widespread recreational use, particularly among counterculture movements in the United States and Europe. Media coverage became increasingly sensational, linking these substances with social disruption, anti-war protest, and perceived moral decline. Politicians responded aggressively. In 1970, the United States Congress passed the Controlled Substances Act, placing LSD and other psychedelics in Schedule I — the most restrictive category, reserved for substances deemed to have a high potential for abuse and no currently accepted medical use.

The following year, the United Nations adopted the Convention on Psychotropic Substances, placing psychedelics under international control. South Africa, as a signatory, incorporated these obligations into domestic law. That framework persists today: psilocybin remains a Schedule 7 substance under the Medicines and Related Substances Act, reflecting the lasting influence of decisions made half a century ago.

How scheduling stopped research

Scheduling did not technically prohibit research, but it made research extraordinarily difficult. Scientists faced heavy regulatory burdens: specialised licences, secure storage requirements, lengthy institutional approvals, and significant costs. Funding agencies grew reluctant to support studies of substances that governments had officially classified as lacking medical value. Ethics committees and institutional review boards became cautious, and the stigma attached to psychedelics created professional risk for researchers who might otherwise have been interested.

The effect was cumulative and self-reinforcing. As fewer studies were published, the field lost momentum, expertise, and institutional infrastructure. A generation of scientists moved into other areas. The absence of new research was then cited as evidence that the substances lacked medical value — a circular logic that reinforced the very restrictions that had caused the gap.

What changed: the slow reopening

The reopening began tentatively in the 1990s. A commonly cited milestone is Rick Strassman's study of DMT at the University of New Mexico, published in 1994 — one of the first modern clinical studies with a classic psychedelic in decades. Other small studies followed, gradually demonstrating that contemporary research could meet modern ethical and methodological standards.

Several factors drove the shift. A new generation of researchers, unconnected to the controversies of the 1960s, applied rigorous methods — randomised designs, double-blind protocols, and neuroimaging. Patient advocacy around treatment-resistant depression and end-of-life distress created pressure for novel approaches. Regulatory bodies, while maintaining strict controls, began to engage with researchers rather than dismiss them. The US Food and Drug Administration's breakthrough therapy designation for psilocybin-based therapy in 2018 signalled a meaningful change in regulatory posture, and Australia's Therapeutic Goods Administration rescheduled psilocybin for limited clinical use in 2023.

South Africa's regulatory landscape has not yet moved significantly, and psilocybin remains Schedule 7. The cannabis precedent — where a Constitutional Court judgment on privacy rights opened legal space for personal use — suggests that legal frameworks can shift, but psychedelic policy reform in South Africa remains at an early stage.

An unfinished story

The decades-long pause in psychedelic research is now widely regarded by historians and policy analysts as a case study in how political forces can override scientific inquiry. The compounds never lost their pharmacological properties or their scientific interest; what changed was the legal and institutional environment surrounding them. Understanding that history matters for current policy debates, particularly in South Africa, where restrictive scheduling continues to limit both research and informed public discussion. The question is no longer whether these substances can be studied safely, but whether legal frameworks will allow the evidence to accumulate.